Xorte logo

News Markets Groups

USA | Europe | Asia | World| Stocks | Commodities



Add a new RSS channel

 
 


Keywords

2023-05-26 02:15:41| Engadget

Turns out Elon Musk's FDA prediction was only off by about a month. After reportedly denying the company's overtures in March, the FDA approved Neuralink's application to begin human trials of its prototype Link brain-computer interface (BCI) on Thursday. Founded in 2016, Neuralink aims to commercialize BCIs in wide-ranging medical and therapeutic applications from stroke and spinal cord injury (SCI) rehabilitation, to neural prosthetic controls, to the capacity "to rewind memories or download them into robots," Neuralink CEO Elon Musk promised in 2020. BCIs essentially translate the analog electrical impulses of your brain (monitoring it using hair-thin electrodes delicately threaded into that grey matter) into the digital 1's and 0's that computers understand. Since that BCI needs to be surgically installed in a patient's noggin, the FDA which regulates such technologies requires that companies conduct rigorous safety testing before giving its approval for commercial use. In March, the FDA rejected Neuralink's application to begin human trials reportedly in part due to all the test animals that kept dying after having the prototype BCI implanted. According to internal documents acquired by Reuters in December, more than 1,500 animals had been killed in the development of the Neuralink BCI since 2018. The US Department of Agriculture's (USDA) Inspector General has since launched an investigation into those allegations.  The FDA's reticence was also born from concerns about the design and function of the interface when implanted in humans. "The agencys major safety concerns involved the devices lithium battery; the potential for the implants tiny wires to migrate to other areas of the brain; and questions over whether and how the device can be removed without damaging brain tissue," current and former Neuralink employees told Reuters in March.While Neuralink has obtained FDA approval to begin its study, the company is not yet seeking volunteers. This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people," Neuralink Tweeted on Thursday. "Recruitment is not yet open for our clinical trial."  This article originally appeared on Engadget at https://www.engadget.com/neuralink-receives-fda-clearance-to-begin-human-trials-of-its-brain-computer-interface-001504243.html?src=rss


Category: Marketing and Advertising

 

Latest from this category

24.11Bailey Hikawas iPhone grip for Apple shows accessible design can fuel mainstream demand
22.11Wind-powered trimaran cuts Atlantic shipping time in half, with near-zero emissions
21.11AI Update, November 21, 2025: AI News and Views From the Past Week
20.11The Most Appropriate and Inappropriate Emojis at Work [Infographic]
20.11How Digital Twins Are Transforming B2B Marketing Product Launches
20.11In Tokyo, a new space for writing letters to the departed as a quiet ritual of grief
19.11The State of AI Use Among Professional Writers
19.11Performance Branding: The Misalignment Between Brand and Performance Marketing
Marketing and Advertising »

All news

25.11Tuesday Watch
25.11Positive Breakout: These 9 stocks cross above their 200 DMAs
25.11Asian stocks track US gains on Fed rate cut bets
25.11FPIs extend IT sell-off, dump Rs 4,873 crore in first half of November
25.11IT counters' weak show could be a silver lining: Motilal Oswal Financial
25.11WeWork India posts strong Q2 growth, eyes faster FY26 expansion
25.11How will revised BSDA rules impact demat account holders?
25.11The entrepreneur connecting tourists to African hospitality
More »
Privacy policy . Copyright . Contact form .